An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to slow enrollment

Conditions

Hyperkalemia

Interventions

DRUG: patiromer

Sponsor

Relypsa, Inc.